Clinique UK ads
This article was originally published in The Rose Sheet
Executive Summary
Estee Lauder's Clinique division should not repeat an unsupported magazine advertising claim for Clinique Repairwear, the British Advertising Standards Authority concludes in a case reported on its Web site Oct. 11. The claim in question, "Enables skin to steer hearty cells to the base of a wrinkle and triggers skin's own natural collagen production," was not supported by studies submitted by Clinique, ASA concludes after hiring an independent expert to evaluate the research. "The expert questioned the implication that a topical product could suppress the local immune cells and either turn on collagen production, or increase it," the industry watchdog group says. Separately in the review, Clinique was able to support the ad claim "Creates a visible reduction in the appearance of wrinkles..".
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.